La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Xperi a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Xperi..

Xperi (NYSE:XPER) Azioni, Catena delle Opzioni

Xperi

Xperi Holding

Xperi Inc consumer and entertainment technology company. Its offering comprises a portfolio of software and services. Its business is divided into four categories based on the products delivered and customers served: Pay-TV, Consumer Electronics, Connected Car, and Platform Solutions. It generates the majority of its revenue from the Consumer Electronics segment.

Xperi Inc

JMP Securities analyst Aaron Hecht maintains Alexandria Real Estate (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARE#NYSE">ARE</a>) with a Market Outperform and lowers the price target from $140 to $130.

News

Price Target

Analyst Ratings

JMP Securities Maintains Market Outperform on Alexandria Real Estate, Lowers Price Target to $130

Morgan Stanley analyst Stephen Byrd maintains Sunrun (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RUN#NASDAQ">RUN</a>) with a Overweight and lowers the price target from $35 to $27.

Morgan Stanley Maintains Overweight on Sunrun, Lowers Price Target to $27

WIIM

Progressive shares are trading higher after the company reported a year-over-year increase in Q3 financial results.

Morgan Stanley analyst Andrew Percoco maintains GE Vernova (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GEV#NYSE">GEV</a>) with a Overweight and raises the price target from $301 to $367.

Morgan Stanley Maintains Overweight on GE Vernova, Raises Price Target to $367

CERO

CERo Therapeutics shares are trading higher after the company received FDA clearance for its investigational new drug application to initiate a Phase 1 clinical trial of CER-1236 for acute myelogenous leukemia.

Cantor Fitzgerald analyst Andres Sheppard maintains Intuitive Machines (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LUNR#NASDAQ">LUNR</a>) with a Overweight and raises the price target from $10 to $15.

LUNR

Cantor Fitzgerald Maintains Overweight on Intuitive Machines, Raises Price Target to $15

CERo Therapeutics, Inc. Receives FDA Clearance Of Its Investigational New Drug Application To Initiate A Phase 1 Clinical Trial Of CER-1236 For Acute Myelogenous Leukemia

Evercore ISI Group analyst Mark Lipacis maintains Applied Mat (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMAT#NASDAQ">AMAT</a>) with a Outperform and lowers the price target from $260 to $250.

AMAT

Evercore ISI Group Maintains Outperform on Applied Mat, Lowers Price Target to $250

TransDigm Gr's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDG#NYSE">TDG</a>) short percent of float has risen 8.85% since its last report. The company recently reported that it has 889 thousand shares sold short, which is 2.09% of all regular shares that are available for trading. Based on its trading volume, it would take traders 5.08 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>TransDigm Gr Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1731678322_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for TransDigm Gr has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing TransDigm Gr's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, TransDigm Gr's peer group average for short interest as a percentage of float is 3.17%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Trading Ideas

How Is The Market Feeling About TransDigm Gr?

Dynatrace's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DT#NYSE">DT</a>) short percent of float has fallen 5.26% since its last report. The company recently reported that it has 6.95 million shares sold short, which is 2.34% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.85 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Dynatrace Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1731678317_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Dynatrace has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Dynatrace's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Dynatrace's peer group average for short interest as a percentage of float is 5.14%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Looking Into Dynatrace's Recent Short Interest

Carrier Global's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CARR#NYSE">CARR</a>) short percent of float has fallen 20.0% since its last report. The company recently reported that it has 10.17 million shares sold short, which is 1.8% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.41 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Carrier Global Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1731678312_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Carrier Global has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Carrier Global's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Carrier Global's peer group average for short interest as a percentage of float is 3.74%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

CARR

(CARR) - Analyzing Carrier Global's Short Interest

On CNBC's &#8220;<a href="https://www.benzinga.com/topic/mad-money-lightning-round">Mad Money Lightning Round</a>,&#8221; Jim Cramer said Altria Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MO#NYSE">MO</a>) is &#8220;undervalued,&#8221; but he is not going to <a href="https://www.benzinga.com/quote/MO/guidance">recommend tobacco stocks</a>.
On Oct. 31, the company reported third-quarter adjusted earnings per share of $1.38. It beat the street view of $1.35. Quarterly sales of $5.334 billion (+1.3%) beat the analyst consensus estimate of $5.326 billion.
Cramer recommended selling Super Micro Computer, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>).
Super Micro Computer filed a FormNT 10-Q with the Securities and Exchange Commission, indicating that it's unable to file its 2025 fiscal-year first-quarter earnings on time.
When asked about The Boeing Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BA#NYSE">BA</a>), he said, &#8220;I prefer not to be in a stock that is going to lose a lot of money for a long time.&#8221;
According to Reuters, the company reportedly begins issuing layoff notices to employees affected by a major restructuring plan. The plan, which aims to reduce Boeing's global workforce by 17,000 jobs—approximately 10% of its total—comes as the heavily indebted aerospace <a href="https://www.benzinga.com/trading-ideas/movers/24/11/41950702/boeing-reportedly-plans-furloughs-whats-going-on">giant seeks to cut costs</a>.
Becton, Dickinson and Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BDX#NYSE">BDX</a>) has &#8220;broken down severely,&#8221; Cramer said. &#8220;If Robert F. Kennedy Jr. is going to be the head of HHS, then it's going to hurt a lot of vaccines, it could hurt a lot of their business.&#8221;
On Nov. 7, the company posted better-than-expected results for its fourth quarter.
&#8220;They have a lot of phase one stuff, and phase one is might early. Too early for me to bet on,&#8221; Cramer said when asked about IDEAYA Biosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IDYA#NASDAQ">IDYA</a>).
On Nov. 4, IDEAYA Biosciences reported a quarterly loss of 60 cents per share, compared to consensus estimates of a loss of 64 cents per share.
&#8220;I just don't know what is wrong,&#8221; Cramer said about AstraZeneca PLC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>). &#8220;My god is this thing going lower.&#8221;
On Nov. 12, AstraZeneca reported third-quarter sales of $13.57 billion, up 18% year over year (+21% at constant currency), beating the consensus of $13.09 billion.
Price Action:
<ul>
<li>Altria shares rose 0.3% to settle at $55.39 on Thursday.</li>
<li>Super Micro Computer shares dipped 11.4% to close at $18.01.</li>
<li>Boeing shares fell 1.3% to settle at $138.14 during the session.</li>
<li>Becton Dickinson shares fell 1.8% to close at $227.17 on Thursday.</li>
<li>IDEAYA Biosciences shares fell 3.4% to settle at $29.47 during the session.</li>
<li>AstraZeneca shares fell 0.4% to close at $65.04 on Thursday.</li>
</ul>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/11/41971544/jim-cramer-recommends-microsoft-praises-american-water-works-for-being-consistent">Jim Cramer Recommends Microsoft, Praises American Water Works For Being &#8216;Consistent&#8217;</a></li>
</ul>
Image: Shutterstock

Long Ideas

Markets

Media

IDYA

SMCI

Jim Cramer Says This Tobacco Stock Is 'Undervalued' But He's Not Recommending It

October retail sales in the United States grew more than expected and their annual growth recorded the highest pace since July 2024, suggesting that U.S. consumers showed continued resilience in their spending habits ahead <a href="https://www.benzinga.com/topic/2024-election">of the presidential elections. </a>
Retail and food services sales reached $718.9 billion in October, marking a 0.4% increase over September. The figure is seasonally adjusted but not adjusted for inflation and is an advance estimate released by a government agency Friday. 
The monthly growth figure topped market expectations for a 0.3% increase, according to consensus estimates from TradingEconomics, but represented a deceleration from the upwardly revised 0.8% increase recorded in September.
<h3 class="wp-block-heading">Electronics Shopping Rebounds In October</h3>
On a year-over-year basis, retail sales grew by a robust 2.8%, the highest in three months and the second-strongest since April, up from the upwardly revised 2% in September. 
Excluding motor vehicles and parts, retail sales rose by just 0.1% month-over-month, down from the upwardly revised 1% growth in September, missing expectations of 0.3%. When stripping out gasoline, motor vehicles, and parts, sales inched 0.1% up in October, a noticeable deceleration from the 1.2% growth seen the previous month.
Within spending categories, electronic and appliance stores recorded the largest monthly gain, with sales increasing 2.3%, rebounding significantly from the 2.9% decline in September. 
Motor vehicle and parts dealers saw a 1.6% rise, accelerating from the previous 0.2% growth. 
On the other hand, miscellaneous store retailers registered the steepest monthly decline, with sales contracting 1.6%, followed closely by furniture and home furniture stores, which saw sales fall 1.3%.
Before the report's release, traders were pricing in a 58% probability of a 25-basis-point rate cut at the Federal Reserve's December meeting, according to the CME FedWatch Tool. 
Those expectations shifted substantially downward from about 80% after Fed Chair Jerome Powell stated on Thursday that the Federal Reserve is not in a hurry<a href="https://www.benzinga.com/news/econ-s/24/11/41991849/powell-with-strong-us-economy-fed-has-no-need-to-be-in-a-hurry-to-lower-rates"> to lower interest rates. </a>
Powell also emphasized that the strength of the U.S. economy allows policymakers to approach rate decisions carefully, suggesting the potential for a pause in rate cuts.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/treasuries/24/11/41993899/powells-hawkish-remarks-shake-markets-stocks-fall-dollar-rockets-bitcoin-dips">Powell&#8217;s Hawkish Remarks Shake Markets: Stocks Fall, Dollar Rockets, Bitcoin Dips</a></li>
</ul>
Photo via Shutterstock.

Retail Sales

Econ #s

Economics

October Retail Sales Top Expectations As US Consumers Increase Tech Spending

On Friday, the FDA accepted for review the resubmission of the supplemental biologics license application (sBLA) for Regeneron Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) and Sanofi SA&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNY#NASDAQ">SNY</a>) Dupixent (dupilumab) for patients ages 12 years and older with chronic spontaneous urticaria (CSU) whose disease is not adequately controlled with H1 <a href="https://www.benzinga.com/pressreleases/24/11/g42000231/press-release-dupixent-sbla-accepted-for-fda-review-for-the-treatment-of-chronic-spontaneous-urtic" target="_blank" rel="noreferrer noopener">antihistamine treatment</a>.
The target action date for the FDA decision is April 18, 2025.
Data from the multi-study LIBERTY-CUPID phase 3 clinical program (<a target="_blank" href="https://www.sanofi.com/en/media-room/press-releases/2021/2021-07-29-05-00-00-2270858" rel="noreferrer noopener">Study A</a>,&nbsp;<a target="_blank" href="https://www.sanofi.com/en/media-room/press-releases/2022/2022-02-18-06-00-00-2387700" rel="noreferrer noopener">Study B</a>, and&nbsp;<a target="_blank" href="https://www.sanofi.com/en/media-room/press-releases/2024/2024-09-11-05-05-00-2944239" rel="noreferrer noopener">Study C</a>) for Dupixent in CSU support the resubmitted supplemental marketing.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/11/41945225/regeneron-sanofis-dupixent-approval-signals-major-treatment-breakthrough-for-smokers-lung-disease" rel="noreferrer noopener">Regeneron/Sanofi&#8217;s Dupixent Approval Signals Major Treatment Breakthrough For Smokers&#8217; Lung Disease</a>
Earlier this year, Japan was the first country in the world to&nbsp;approve&nbsp;and launch Dupixent for adult and adolescent CSU patients based on the results <a target="_blank" href="https://www.benzinga.com/general/biotech/24/09/40814475/sanofi-regeneron-drug-dupixent-shows-successful-treatment-of-patients-with-inflammatory-skin-dise" rel="noreferrer noopener">from Study A</a>.
The supplemental marketing adds results from Study C, conducted in patients with uncontrolled CSU who were on standard-of-care antihistamines. Study C, the second LIBERTY-CUPID pivotal study in biologic-naïve patients, met its primary and key secondary endpoints, confirming the results of the previous Study A.
Results showed that Dupixent significantly reduced itch and urticaria activity (itch and hives).
In March 2023, the FDA <a target="_blank" href="https://www.sanofi.com/en/media-room/press-releases/2023/2023-03-07-06-00-00-2621670" rel="noreferrer noopener">accepted</a> the supplemental marketing application for Dupixent&nbsp;(dupilumab) to treat adults and adolescents with chronic spontaneous urticaria, with the target action date for the FDA decision of October 22, 2023.
In October 2023, the FDA <a target="_blank" href="https://www.sanofi.com/en/media-room/press-releases/2023/2023-10-20-21-00-00-2764252" rel="noreferrer noopener">issued</a> a Complete Response Letter for the supplemental Biologics License Application and stated that additional efficacy data are required to support approval.
It did not identify any issues with safety or manufacturing.
CSU is a chronic inflammatory skin disease driven partly by type-2 inflammation, which causes sudden hives and recurring itch.
CSU is typically treated with H1 antihistamines, medicines that target H1 receptors on cells to control urticaria symptoms.
More than 300,000 people in the US suffer from CSU that is inadequately controlled by antihistamines.
Price Action: REGN stock closed at $782.51 on Thursday, and SNY stock is up 1.09% at $48.34 during the premarket session at last check Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/health-care/24/11/41987383/unitedhealths-optum-defends-multi-billion-dollar-amedisys-deal-ensures-competitive-landscape" target="_blank" rel="noreferrer noopener">UnitedHealth&#8217;s Optum Defends Multi-Billion Dollar Amedisys Deal, Ensures Competitive Landscape</a></li>
</ul>
Photo: Shutterstock

Biotech

Large Cap

Health Care

General

REGN

FDA To Revisit Regeneron/Sanofi's Dupixent For Rare Skin Disease

OneStream shares are trading lower after the company announced a 15 million class A common stock secondary offering.

InMed Pharmaceuticals shares are trading lower after the company reported a year-over-year decrease in Q4 EPS results.

Earnings

Know Labs FY24 EPS  $(0.20) vs $(0.41) YoY

Company's Rapid Alcohol-Reducing Beverage, Sure Shot, to be Sold in 192 Stores Across Nevada, Arizona, and California
JUPITER, Fla., Nov. 15, 2024 (GLOBE NEWSWIRE) -- Safety Shot, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHOT#NASDAQ">SHOT</a>) ("Safety Shot" or "the Company") today announced a new agreement with a leading national grocery chain to sell its convenient, newly branded 4 oz. Sure Shot beverages in select stores across the Southwest. This chain boasts over 2,200 stores nationwide, making them a significant player in the grocery industry.
This strategic launch in 192 stores across Nevada, Arizona, and California represents a significant milestone in Safety Shot's growth strategy. It provides access to a substantial and rapidly growing alcohol beverage market and marks a key step towards the Company's goal of nationwide distribution.

SHOT

Safety Shot Announced A New Agreement With A Leading National Grocery Chain To Sell Its Convenient, Newly Branded 4 Oz. Sure Shot Beverages In Select Stores Across The Southwest

Evercore ISI Group analyst Duane Pfenningwerth downgrades Diamondrock Hospitality (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DRH#NYSE">DRH</a>) from Outperform to In-Line and maintains the price target from $10.5 to $10.5.

Downgrades

Evercore ISI Group Downgrades Diamondrock Hospitality to In-Line, Maintains Price Target to $10.5

RVYL

Ryvyl shares are trading lower. HC Wainwright & Co. reiterated a Neutral rating on the stock.

In a report released today, Jason Kreyer from Craig-Hallum maintained a Buy rating on Xperi Inc (XPER – Research Report). The company's shares clos...

Craig-Hallum Keeps Their Buy Rating on Xperi Inc (XPER)

Reports Q3 revenue $132.9M, consensus $130.73M. "With the Perceive transaction now closed, we are fully focused on entertainment-based solutions to...

Xperi reports Q3 EPS 51c, consensus 18c

FY24 revenue consensus $511.76M Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See...

Xperi cuts FY24 revenue view to $490M-$505M from $500M-$530M

Xperi Non-GAAP EPS of $0.51 beats by $0.33, revenue of $132.9M beats by $2.17M

Xperi Inc. 2024 Q3 - Results - Earnings Call Presentation

Xperi Inc. (XPER) Q3 2024 Earnings Call Transcript

Xperi Inc ( ($XPER) ) has released its Q3 earnings. Here is a breakdown of the information Xperi Inc presented to its investors. Xperi Inc., an ent...

Xperi Inc. Reports Strong Q3 2024 Earnings and Strategic Wins

Hamed Khorsand, an analyst from BWS Financial, maintained the Buy rating on Xperi Inc (XPER – Research Report). The associated price target remains...

Hamed Khorsand's Buy Rating for Xperi Inc: Strong Revenue Performance and Promising Future Prospects

Matthew Galinko, an analyst from Maxim Group, maintained the Buy rating on Xperi Inc (XPER – Research Report). The associated price target remains ...

Xperi Inc's Strong Financial Performance and Strategic Moves Earns Buy Rating from Analyst

The tech market is booming thanks to the rapid development of AI-integrated systems, increasing software application demand, and SAAS evolutions. Therefore, investors could consider buying sound under $10 tech stocks Olo (OLO), Xperi (XPER), and Eventbrite (EB), which Wall Street predicts will surge by over 25%. Continue reading... The technology industry is transforming every day with new advancements. The sector is aiding various industries and contributing to their transition from traditional modes to the modern tech-driven ways. These trends have positioned the tech industry for continued growth and prosperity.
Given the industry's bright outlook, it could be wise to invest in fundamentally strong tech stocks Olo Inc. (<a href="https://stocknews.com/stock/OLO/">OLO</a>), Xperi Inc. (<a href="https://stocknews.com/stock/XPER/">XPER</a>), and Eventbrite, Inc. (<a href="https://stocknews.com/stock/EB/">EB</a>) currently trading under $10 and can soar over 25%.
The technology market is expanding rapidly at unprecedented levels, driven by encouraging trends like AI-integrated systems, advanced software, surging demand for SAAS, and the growing scale of enterprise software solutions that elevate businesses and operations and focus on enhanced efficiency and core competencies.
In the year 2024, the companies mostly attempted to determine how <a href="https://www2.deloitte.com/us/en/insights/industry/technology/executives-expect-tech-industry-growth-in-2024.html">to leverage generative AI</a>, migrate their workloads to the cloud, and adjust to the updated regulatory requirements. Further, the increasing internet penetration accelerated the software application investments as more and more consumers preferred online resources to source what they needed.
With this, the global enterprise software market is expected to grow at a CAGR of 12.1%, <a href="https://www.grandviewresearch.com/industry-analysis/enterprise-software-market">resulting in a market volume of $517.26 billion by 2030</a>. Market growth relies on the increasing preference for automated and integrated solutions, the demand for streamlined, reliable software applications, and the need to automate routine tasks.
Besides, owing to the rise in the adoption of public &amp; hybrid cloud-based solutions, integration with other tools, and centralized data-driven analytics, the <a href="https://www.fortunebusinessinsights.com/software-as-a-service-saas-market-102222">global Software as a Service (SaaS) market</a> is booming. Also, the market is currently observing rising partnerships and collaborations for business development, which will create ample market growth opportunities.
Given these encouraging trends, let's delve deeper into the fundamentals of top tech stocks: OLO, XPER, and EB.
Olo Inc. (<a href="https://stocknews.com/stock/OLO/">OLO</a>)
OLO operates an open SaaS platform for restaurants. The company's platform allows on-demand digital commerce operations, which cover digital ordering, delivery, front-of-house management, and payments. Its solutions include Order, Engage, and Pay.
In terms of forward EV/Sales, OLO is trading at 2.82x, 9.5% lower than the industry average of 3.12x. Also, its trailing-12-month Price/Book of 1.69x is 48.9% lower than the industry average of 3.31x.
On November 7, OLO expanded its long-standing partnership with ezCater, the #1 food tech platform for workplaces in the US, for the launch of a new menu integration. The integration is intended to simplify catering menu management by automating menu updates across both tech platforms to save valuable time for restaurant operators.
On July 30, OLO and GRUBBRR, a leading provider of self-ordering technology, entered into a strategic partnership. The collaboration is aimed at elevating the onsite dining experience by combining GRUBBRR's extensive platform, which includes self-ordering kiosks and dynamic digital menu boards, with Olo's robust ordering and payment processing capabilities.
OLO's total revenue increased 24.3% year-over-year to $71.85 million for the third quarter, which ended September 30, 2024, and its non-GAAP gross profit was $43.61 million, up 11% from the prior year's quarter. Also, the company's non-GAAP net income grew 37.4% and 50% from the year-ago value to $10.39 million and $0.06 per share, respectively.
The company issued its financial outlook for the fourth quarter and full year 2024. OLO expects to report revenue in the range of $72.50 million to $73 million and non-GAAP <a href="https://www.investopedia.com/terms/o/operatingincome.asp">operating income</a> in the range of $8.70 million to $9 million for the fourth quarter of 2024.
For the full year 2024, the company's revenue is expected to be between $281.40 million and $281.90 million. Also, its non-GAAP operating income is expected to be $30.20 million - $30.50 million.
Street expects OLO's revenue and EPS for the fourth quarter (ending December 2024) to increase 15.5% and 33.3% year-over-year to $72.75 million and $0.07, respectively. Furthermore, the company surpassed the consensus revenue and EPS estimates in each of the trailing four quarters.
Shares of OLO have increased 42.8% over the past six months and 41.6% over the past year to close the last trading session at $6.67. The average analyst price target of $8.50 indicates a <a href="https://www.tipranks.com/stocks/olo/forecast">27.44% upside potential</a>.
OLO's robust growth prospects are reflected in its <a href="https://stocknews.com/powr-ratings/">POWR Ratings</a>. The stock has an overall rating of B, which translates to a Buy in our proprietary rating system. The POWR Ratings are calculated by considering 118 different factors, each weighted to an optimal degree.
The stock has an A grade for Sentiment. It also has a B for Growth. Within the A-rated <a href="https://stocknews.com/category/software-saas/">Software - SAAS</a> industry, OLO is ranked #11 out of 18 stocks.
<a href="https://stocknews.com/stock/OLO/">Click here</a> to access additional ratings of OLO for Quality, Stability, Value, and Momentum.
Xperi Inc. (<a href="https://stocknews.com/stock/XPER/">XPER</a>)
XPER operates as a global consumer and entertainment technology company. The company offers Pay-TV solutions, including UX solutions; IPTV, a cloud-based solution; managed IPTV service; video metadata and services; managed IPTV Service; metadata libraries; personalized content discovery; and technical support service.
XPER's forward EV/EBIT of 8.26x is 61.1% lower than the industry average of 21.24x. Likewise, the stock's forward Price/Sales multiple of 0.75 is considerably lower than the industry average of 3.11. Also, its forward EV/EBITDA of 4.84x is 68.7% lower than the 15.47x industry average.
On September 10, XPER's wholly-owned subsidiary, TiVo, expanded its footprint across Europe through its personalized content discovery platform for smart TV, operator, and automotive solutions, available in 38 European markets and across 18 major brands.
The expansion broadens XPER's footprint for content discovery services, enabling TiVo to aid its partners in addressing the continuously growing challenge of discovery in a fragmented streaming landscape.
On September 4, TiVo announced the expansion of its smart TVs Powered by TiVo across its OEM partners, spanning 17 brands, including Bush, Daewoo, Digihome, Panasonic, Sharp, Telefunken, and Vestel.
XPER's revenue rose 1.9% year-over-year to $132.89 million during the third quarter that ended September 30, 2024. Its non-GAAP operating income grew 463.9% from the year-ago value to $24.52 million. Non-GAAP net income attributable to the company amounted to $23.31 million or $0.51 per share, against a net loss of $3.30 million and $0.08 per share during the prior year's quarter.
According to the company's revised financial outlook for fiscal 2024, XPER expects revenue of $490 million to $505 million.
Analysts expect XPER's revenue for the first quarter (ending March 2025) to increase 4.5% year-over-year to $124.20 million. For the fiscal year 2025, the company's revenue is expected to grow 4.1% year-over-year to $515.35 million. Also, the company has topped the consensus EPS estimates in three of the trailing four quarters.
XPER's shares have gained 16.6% over the past three months to close the last trading session at $8.28. Wall Street analysts expect the stock to hit $24 in the near term, indicating a potential <a href="https://www.tipranks.com/stocks/xper/forecast">upside of 189.86%</a>.
XPER's sound fundamentals are reflected in its POWR Ratings. It has an overall rating of B, equating to a Buy in our proprietary rating system.
The stock has an A grade for Growth and a B grade for Value and Sentiment. Within the <a href="https://stocknews.com/category/software-application/">Software - Application</a> industry, XPER is ranked #25 among the 129 stocks.
In addition to the POWR Ratings we've stated above, we also have XPER ratings for Momentum, Quality, and Stability. Get all XPER ratings <a href="https://stocknews.com/stock/XPER/">here</a>.
Eventbrite, Inc. (<a href="https://stocknews.com/stock/EB/">EB</a>)
EB operates a two-sided marketplace that provides self-service ticketing and marketing tools for event creators internationally. Its platform integrates components needed to plan, promote, and produce live events that allow creators to reduce friction and costs, enhance reach, and drive ticket sales.
In terms of forward EV/Sales, EB is trading at 0.12x, 93.9% lower than the industry average of 2.03x. Also, the stock's forward Price/Sales multiple of 1.09 is 17.2% lower than the industry average of 1.31. Similarly, its forward EV/EBITDA of 1.13x is 85.7% lower than the industry average of 7.89x.
On October 28, EB launched a free timed-entry tool, empowering organizers to easily set up and sell multiple daily time slots for their events. This fully customizable solution by EB unlocks new opportunities and is ideal for tours, attractions, excursions, and classes, where attendees can easily book tickets for their preferred time slot.
During the third quarter, which ended September 30, 2024, EB reported net revenue of $77.80 million, and its gross profit came in at $53.26 million for the same period. Also, the company's adjusted EBITDA was $5.34 million for the quarter.
Furthermore, the company's cash and cash equivalents stood at $530.96 million as of September 30, 2024, compared to $489.20 million as of December 31, 2023.
As per the company's outlook, it expects revenue in the range of $74 to $77 million for the fourth quarter of 2024.
For the full year 2024, revenue will be within a range of $322 million to $326 million. Also, at the midpoint of the revenue outlook range, an adjusted EBITDA margin of approximately 10% is projected for the year.
Analysts expect EB's revenue for the fiscal year (ending December 2025) to increase 4.8% year-over-year to $340.19 million, and its EPS for the same period is expected to be $0.01.
EB's stock has soared 37.3% over the past month to close the last trading session at $3.59. The average analyst price target of $5.75 indicates a <a href="https://www.tipranks.com/stocks/eb/forecast">60.17% upside potential</a>.
EB's POWR Ratings reflect its robust outlook. The stock has an overall rating of B, which translates to a Buy in our proprietary rating system.
EB has an A grade for Value. The stock also has a B grade for Quality. It is ranked #6 among the 26 stocks in the <a href="https://stocknews.com/category/internet-services/">Internet - Services</a> industry.
<a href="https://stocknews.com/stock/EB/">Click here</a> to access additional EB ratings for Stability, Momentum, Growth, and Sentiment.
What To Do Next?
Get your hands on this special report with 3 low priced companies with tremendous upside potential even in today's volatile markets:
<a href="https://report.stocknews.com/free-report/3stocks/?formplacement=artbotad_3s">3 Stocks to DOUBLE This Year &gt;</a>

<hr />
OLO shares were unchanged in after-hours trading Thursday. Year-to-date, OLO has gained 13.11%, versus a 26.01% rise in the benchmark S&amp;P 500 index during the same period.
<hr><div style="clear:both;"></div> <h2>About the Author: Rjkumari Saxena</h2> <img src='https:/wp-content/uploads/2024/04/Rajkumari-Saxena_Image-1.jpeg' style="float:left; padding:5px;width:125px;">Rajkumari started her career as a writer but gradually shifted her focus to financial journalism, leveraging her educational background in Commerce. Fascinated by the interplay of business and economic shifts in equities, she aspires to evolve as an analyst. With a knack for simplifying complex financial concepts, her mission is to empower investors with insights that lead to profitable decisions.<a href="https://stocknews.com/authors/?author=rajkumari-saxena">More...</a>The post <a href=https://stocknews.com/news/olo-xper-eb-3-tech-stocks-under-10-that-wall-street-predicts-will/>3 Tech Stocks Under $10 That Wall Street Predicts Will Surge Over 25%</a> appeared first on <a href=https://stocknews.com/>StockNews.com</a>

Comments

Xperi

Xperi (XPER) Opzioni

Xperi (NYSE:XPER) Azioni, Catena delle Opzioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO